AstraZeneca plans to spend $100 million over the next five years to modernize its Newark production and distribution site.
In a blog post, the company said the site south of Newark and off Old Baltimore Pike is a key site in the company’s global supply chain. AstraZeneca has three such sites in the US and 17 worldwide.
The investment comes as AstraZeneca phases out more than 1,000 positions at its offices in north Wilmington as it adjusts to the loss of patent protection on key drugs and the resulting decline in revenue.
Some positions will be moved to the operations of Medimmune, an AstraZeneca business based in the Washington, D.C. Area.
The facility provides primary and secondary packaging and handles the vast majority of packing for the North American market. It also does formulation work for global markets.
AstraZeneca plans to create a state-of-the-art formulation center and centralize packaging operations at the Newark location.